Sage Journals: Discover world-class research

Abstract

Background:

The circulating metabolome incorporates multiple levels of biological interactions and is an emerging field for biomarker discovery. However, few studies have linked metabolite levels with quantitative neurologic function assessments in people with multiple sclerosis (pwMS).

Objectives:

We quantified metabolomic differences between pwMS and healthy controls (HCs) and assessed the association of metabolites with disease severity.

Methods:

We profiled 517 metabolites using liquid chromatography-mass spectrometry (Biocrates Inc.) for participants from the MS Partners Advancing Technology and Health Solutions (MS PATHS). We conducted a multicenter cross-sectional study and applied linear regression to assess the association between metabolites and neurological function measures in multiple sclerosis (MS), including walking speed, manual dexterity, and processing speed.

Results:

Among 1010 participants (837 MS; 71.2% relapsing-remitting MS; 173 HC; mean age: 44.5 (standard deviation (SD): 11.4); 73.9% female; 12.7% non-white), pwMS showed decreased levels of phosphatidylcholines (PCs) and different amino acids (AAs) but increased triglycerides (TGs). Metabolites showed an association with worse neurologic function; for instance, a 1-SD decrease in PC aa C36:6 was associated with 21.36% (95% confidence interval (CI): 11.07–30.46; p = 1.35E−04) slower walking speed.

Conclusions:

This large study identified lipid alterations linked to MS severity. Future longitudinal studies will evaluate if these metabolite levels predict MS outcomes.

Keywords

Multiple sclerosis metabolomics lipidomics multiple sclerosis performance test neurological function

Get full access to this article

View all access options for this article.

References

Lucchinetti

Calabresi

. Multiple sclerosis. N Engl J Med 2018; 378: 169–180.

Wallin

Culpepper

Campbell

, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019; 92: e1029–e1040.

Williamson

Noonan

Henry

, et al. Peer reviewed: The prevalence of multiple sclerosis in 3 US communities. Prevent Chron Dis 2010; 7: A12.

Fitzgerald

Smith

Kim

, et al. Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Rep Med 2021; 2: 100424.

Oppong

Coelewij

Robertson

, et al. Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity. iScience 2024; 27: 109225.

Mowry

Bermel

Williams

, et al. Harnessing real-world data to inform decision-making: Multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol 2020; 11: 632.

Rudick

Miller

Bethoux

, et al. The Multiple Sclerosis Performance Test (MSPT): An iPad-based disability assessment tool. JOVE: J Visual Exp 2014; 88: e51318.

Adam

Limonciel

Ustaszewski

. Validation and application of a unique reference database for metabolomics: The Quantitative Metabolomics Database (QMDB). https://biocrates.com/wp-content/uploads/2022/11/Whitepaper_QMBD.pdf

Langfelder

Horvath

. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform 2008; 9: 1–13.

10.

Subramanian

Tamayo

Mootha

, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 2005; 102: 15545–15550.

11.

Ferreira

Melo

Monteiro

, et al. Serum phospholipidomics reveals altered lipid profile and promising biomarkers in multiple sclerosis. Arch Biochem Biophys 2021; 697: 108672.

12.

Del Boccio

Pieragostino

Di Ioia

, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteom 2011; 74: 2826–2836.

13.

Virupakshaiah

Ladakis

Nourbakhsh

, et al. Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis. Mult Scler 2023; 29(8): 936–944.

14.

Ferreira

Neves

Guerra

, et al. An overview of lipidomic analysis in different human matrices of multiple sclerosis. Mult Scler Relat Disord 2020; 44: 102189.

15.

Oliveira

EML

Montani

Oliveira-Silva

, et al. Multiple sclerosis has a distinct lipid signature in plasma and cerebrospinal fluid. Arq Neuropsiquiatr 2019; 77(10): 696–704.

16.

Weinstock-Guttman

Zivadinov

Mahfooz

, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflam 2011; 8: 1–7.

17.

de la Rubia Ortí

Platero Armero

Cuerda-Ballester

, et al. Lipid profile in multiple sclerosis: Functional capacity and therapeutic potential of its regulation after intervention with epigallocatechin gallate and coconut oil. Foods 2023; 12: 3730.

18.

Cho

Choi

, et al. Low high-density lipoprotein cholesterol and high triglycerides lipid profile in neuromyelitis optica spectrum disorder: Associations with disease activity and disability. Mult Scler Relat Disord 2020; 40: 101981.

19.

Tettey

Simpson

Jr Taylor

, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 2014; 20(13): 1737–1744.

20.

Tan

Feng

Liu

, et al. The pro-inflammatory effect of triglyceride on human CD4+ T cells and experimental autoimmune uveitis. Clin Immunol 2022; 240: 109056.

21.

Lee

Aung

Wilson

, et al. Triglyceride-rich lipoprotein lipolysis products increase blood-brain barrier transfer coefficient and induce astrocyte lipid droplets and cell stress. Am J Physiol-Cell Physiol 2017; 312: C500–C516.

22.

Lagace

Ridgway

. The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochim Biophys Acta 2013; 1833(11): 2499–2510.

23.

Andersen

Briggs

FBS

Winnike

, et al. Metabolome-based signature of disease pathology in MS. Mult Scler Relat Disord 2019; 31: 12–21.

24.

Kasakin

Rogachev

Predtechenskaya

, et al. Changes in amino acid and acylcarnitine plasma profiles for distinguishing patients with multiple sclerosis from healthy controls. Mult Scler Int 2020; 2020: 9010937.

25.

Pashaei

Yarani

Mohammadi

, et al. The potential roles of amino acids and their major derivatives in the management of multiple sclerosis. Amino Acids 2022; 54(6): 841–858.

26.

Qin

Goswami

Balabanov

, et al. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 2007; 85(5): 977–984.

27.

Rzepiński

Kośliński

Kowalewski

, et al. Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis. Neurol Neurochir Pol 2023; 57(5): 414–422.

28.

Sylvestre

Slupsky

Aviv

, et al. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain. Brain Research 2020; 1732: 146589.

29.

Villoslada

Alonso

Agirrezabal

, et al. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2017; 4(2): e321.

30.

Kasakin

Rogachev

Predtechenskaya

, et al. Targeted metabolomics approach for identification of relapsing–remitting multiple sclerosis markers and evaluation of diagnostic models. Medchemcomm 2019; 10: 1803–1809.

31.

Levi

Gurevich

Perlman

, et al. Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis. Cell Rep Med 2021; 2: 100246.

32.

Yudkoff

. Interactions in the metabolism of glutamate and the branched-chain amino acids and ketoacids in the CNS. Neurochem Res 2017; 42(1): 10–18.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.98 MB

0.03 MB